PDCD1 and non-small cell lung carcinoma: Comparable results were obtained in another study evaluating two anti-PD-1/PD-L1 radiotracers (a 18Fluor-labeled anti-PD-L1 Adnectin and an anti-PD-1, 89Zirconium-labeled nivolumab) on 13 patients with advanced NSCLC [39].